Drug Development Health Data Pharmaceuticals 
Lloyd Price
OCTOBER 14, 2024
While the specific agenda may have varied, here are some of the main tracks and topics that were likely covered: Main Tracks: AI and Machine Learning: Discussions on the applications of AI and ML in drug discovery, medical imaging, and personalised medicine. Regulatory Landscape: Changes in healthcare regulations and policies.
Healthcare IT Today
JANUARY 7, 2025
As these implementations take hold, the emphasis will be on demonstrating measurable return on investment (ROI), with AI driving down administrative burdens, accelerating drug development, and significantly improving operational efficiency. What’s most exciting to me is AI’s potential impact on personalized medicine.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Digital Health Global
AUGUST 22, 2024
Spellman and Wortel are the most recent additions to Catawba Research’s team of scientific and regulatory advisors who support sponsors across a multitude of therapeutic areas and provide clinical development and regulatory strategy across North America, Europe and Asia.
Lloyd Price
MAY 16, 2023
The company has partnerships with organizations such as the Mayo Clinic, the University of California, San Francisco, and the Veterans Health Administration. Palantir's products are also being used by pharmaceutical companies, medical device manufacturers, and healthcare payers. Palantir's plans for healthcare are ambitious.
Digital Health Global
NOVEMBER 2, 2023
Wearable monitoring devices, genomics, and AI play vital roles in this transformation, enabling personalized interventions and collective health data sharing for research. There are three main advantages to the use of AI in drug development: width of research, speed of execution, low costs. DiMasi, H.G.
Lloyd Price
JANUARY 20, 2025
They initially focused on direct-to-consumer sales, offering insights into ancestry, health predispositions, and carrier status. They've leveraged this vast consumer dataset to establish partnerships with pharmaceutical companies for drug discovery and development. to predict future health risks.
Healthcare IT News - Telehealth
MAY 6, 2020
Biofourmis’ digital therapeutics are used for RPM across three primary healthcare stakeholder groups: health systems, payers and pharmaceutical companies. Typically, the health systems and payers work together in a value-based care arrangement that involves shared risk and reward.
Expert insights. Personalized for you.
56 
Let's personalize your content